This paper presents the results of a comprehensive examination of current distribution of Hepatitis A virus (HAV) seroprevalence and endemicity in Turkey and the possible links between HAV endemicity and socioeconomic development. We performed a systematic search in online resources published between January 2000 and August 2015. The 22 provinces were able to be assigned a hepatitis A endemicity level based on this systematic review. The incidence rates for symptomatic hepatitis A infection are higher in the eastern part of Turkey than in the western and central region. These differences in socioeconomic indicators by region suggest the likelihood of lower seroprevalence rates in the western parts of the country and higher rates in the eastern region. Turkey's current policy of recommending hepatitis A immunization for all children without contraindications is an appropriate one and is likely to remain the best option for at least the next decade or two.
Hepatitis A virus (HAV) is usually acquired through contact with an infected person or through ingestion of contaminated water or food, and it is one of the major causes of acute viral hepatitis globally 1 . The severity and clinical course of the infection vary according to the age of the patient. When acquired in the early years of the life, HAV infection is often asymptomatic. With advancing age, jaundice and other symptoms usually occur; liver failure and death are possible complications though occur very rarely. The incidence of the disease varies with access to clean drinking water and other indicators of socioeconomic status 2, 3 . Places like Turkey that have undergone significant socioeconomic development in recent decades often transition from having a high incidence of asymptomatic infections in young children to seeing a growing number of outbreaks resulting in symptomatic cases in adults 1 . In these countries, universal childhood vaccination is often cost-effective 4 . Turkey added HAV to its routine immunization schedule in 2012. Since this is likely to change the epidemiological profile of the country, it is important to have a baseline understanding of the heterogeneity of profiles across Turkey.
Because HAV is often asymptomatic, most epidemiological studies rely on serological indicators of past infection (anti-HAV IgG) rather than trying to quantify current infection (anti-HAV IgM). IgG antibodies usually persist for life. The percentage of various age groups of individuals who test positive for anti-HAV IgG provides information about both recent and past epidemiological patterns 5 . A high rate of seropositivity among children reveals a high incidence rate during those children's lifetimes. A low rate in children but a high rate in adults usually indicates that the incidence rate has decreased during those adults' lifetimes. Plots of age (on the x-axis) and HAV seroprevalence (on the y-axis) at different places and different time points therefore provide useful information about changing endemicity patterns and offer insights about the most appropriate vaccination strategy for a population. T h i s p a p e r p r e s e n t s t h e r e s u l t s o f a comprehensive examination of current HAV endemicity patterns across Turkey, the differences by region, and the possible connections between socioeconomic indicators and within-country heterogeneity in HAV seroprevalence rates. This information can be considered a baseline evaluation for tracking the future evolution of HAV endemicity in Turkey after the initiation of the routine vaccination program.
Material and Methods
Systematic literature search. We performed a systematic search in PubMed, Google Scholar, and EBSCOhost in the Turkish and English languages to identify published articles, conference abstracts, and other online resources published after January 2000 and indexed by January 2016. Publications in all languages were eligible for inclusion, but all articles identified during the search were written in English or Turkish. We also examined the reference lists of all eligible articles to search for non-indexed documents that might meet the eligibility criteria. The systematic review was conducted in accordance with the PRISMA guidelines 6 .
Inclusion and exclusion criteria. Two authors independently evaluated all of the reports to determine whether they met the eligibility criteria. To be eligible, an article had to: (1) be conducted in Turkey; (2) report age-specific anti-HAV IgG seroprevalence rates or combined IgG/IgM results; (3) report the results of data collected in or after the year 2000; (4) include a population reasonably representative of the general population; (5) include at least 100 participants; and (6) present original results rather than reviewing previously published reports. Articles were excluded if they (1) were not conducted in Turkey; (2) reported HAV incidence rather than prevalence; (3) presented data collected prior to the year 2000; (4) focused on a special population likely to have higher risk for exposure to HAV such as healthcare workers, patients with acute or chronic liver disease, and patients with organ transplants, HIV, or other chronic health issues; (5) included fewer than 100 participants; or (6) were a review article, outbreak investigation, environmental study, or examination of vaccination effectiveness. To ensure the completeness of the evaluation, abstracts from conferences were included when no full paper was published about a research study after it was presented.
Vaccination was not introduced into the routine childhood vaccination schedule in Turkey until 2012, so the participants in studies from earlier years can be assumed not to have received a vaccine 7, 8 . Only 3 studies collected seroprevalence data from young children after the introduction of universal childhood vaccination [8] [9] [10] . Aside from children less than two years old in those studies, all the measures of seropositivity in this review are indicators of naturally-acquired infection.
Quality assessment. After removing duplicate entries that appeared in more than one database, 118 journal articles and 7 conference abstracts were examined for eligibility. Sixteen studies were excluded after abstract review. Fifty-eight additional articles were excluded after a full-text review because they did not meet all of the eligibility criteria. In total, 51 studies were included in the final analysis ( Fig.  1) . For each study, critical information about the study site, study design, data collection years, sampling method, sample size, study population, and age-seroprevalence rates was extracted. All of the studies were then graded based on their sampling methods and the representativeness of the study population, as per the method proposed by Itani et al. 11 in a previous paper about hepatitis A in the Middle East region (Table I) .
Endemicity assignment. The age at midpoint of population immunity to HAV is the youngest age at which at least half of the population has serologic evidence of prior infection with HAV, and this is a recommended indicator of HAV endemicity status 1, 5, 11 . To find the age at midpoint of population immunity for each included study, the midpoint of each age group in a study population was plotted on the x-axis and the corresponding seroprevalence rate on the y-axis. GraphPad Prism (version 6.0, GraphPad Software, Inc., La Jolla, CA, USA) was used to fit various types of curves to the data points. The best-fit curve from among different logarithmic, polynomial, and sigmoidal curves was the one with the r 2 value nearest to 1. The equation for the best-fit curve was used to calculate the age at which seroprevalence was first equal to 50%. Endemicity rates were assigned to each study based on the ages at midpoint of population immunity and the categories presented in previous HAV reports: very high for less than 5 years, high for 5 to 14 years, intermediate for 15 to 34 years; and low for 35 years and older 5, 11 . When the endemicity levels for each province were mapped, endemicity was assigned based on a consideration of the studies with the highest quality grades, the largest sample sizes, and the most recent data. We also used graphing methods to identify the seroprevalence rate at the midpoint of four age groups: ages birth to 10 years, 11 to 20 years, 21 to 50 years, and 51 years or older.
Socioeconomic indicators. Four province-level indicators were used to evaluate possible a s s o c i a t i o n s b e t w e e n s o c i o e c o n o m i c development and hepatitis A endemicity.
Data about the proportion of the population whose drinking water comes from a municipal water system and is regularly inspected by the Ministry of Health and about access to sewage systems were acquired from the Turkish Statistical Institute affiliated to the Ministry of Development 12,13 because access to water is known to be a risk factor for HAV 2, 3 . Data about the percentage of each province living in cities was also collected along with the province development index (PDI), which is a composite of 60 different sociodemographic, health, education, employment, urbanization, infrastructural, financial, and equality indicators compiled and ranked by the Ministry of Development 14, 15 . Each province is assigned a PDI between 1 (for high levels of development) and 6 (for low levels of development). Various descriptive statistics, comparative tests, and correlations were used to examine relationships between these socioeconomic indicators and various HAV metrics. All statistics were calculated with SPSS version 22 with a significance level of p<0.05.
Results
Using the methods describe above, an endemicity level and age-specific HAV seroprevalence could be assigned to 23 of the 81 provinces in Turkey based on the studies included in the systematic review and meta-analysis. This included 8 of 19 provinces in the western region ( out 32 provinces in the central region (Table  III) , and 8 of 30 provinces in the eastern region (Table IV) . For the remaining 58 provinces, no available data met the inclusion criteria.
A map of PDIs shows a substantial development gradient in Turkey, with the western region the most developed area and the eastern region much less developed (Fig. 2) . By contrast, a map of HAV endemicity does not reveal such a clear trend (Fig. 3) . Each region has a mix of provinces intermediate, high, and very high endemicity level (Table V) . Access to water and sanitation are not significantly associated with endemicity, and urbanization and PDI are also not strong predictors. Perhaps the most notable trend is that urban areas like Istanbul (the largest metropolitan area), Ankara (the nation's capital and the 2 nd largest city), and Izmir (the 3 rd largest city) tend to have lower rates than studies from more rural areas. Provinces with a more urban population tended to have intermediate endemicity and provinces with a more rural population tended to have high endemicity. This prediction does not süit the provinces where it has migration areas and underdeveloped neighborhoods since such areas cause artificial increase in endemicity. 27 However, a consideration of the quality of the evidentiary base for categorizations support an endemicity pattern more in line with the PDI scores. In the western and central regions, the recent studies almost uniformly indicate an intermediate endemicity while older studies report seroprevalence rates consistent with high endemicity. Importantly, the seroprevalence rates in children ages 0-10 years are different in the three regions even though the adults' rates are not significantly different (Fig. 4 ). This suggests that the incidence rate has decreased in the western and central regions over the past 15 years, and these areas have transitioned from high to intermediate endemicity patterns. In the eastern region, a mix of intermediate, high, and very high endemicity levels is reported, and recent studies cover this range of epidemiological profiles. As a result, this data indicates that the incidence rate remains higher in this part of the country than it is in Turkey's other regions.
Discussion
The 23 provinces able to be assigned a hepatitis A endemicity level based on this systematic review and analysis of data from the past 15 years are home to 42.3 million of Turkey's 77.6 million residents, or about 55% of the total population 64 . The results of this analysis show that it would be an oversimplification to classify Turkey as a country with intermediate endemicity without acknowledging the heterogeneity of different regions within Turkey. However, they also reveal some general trends. The incidence rates for symptomatic hepatitis A infection are higher in the eastern part of Turkey than in the western and central region 65 , and this is reflected in the differences in child seropositivity by region in this analysis.
These disparities and the variations in socioeconomic indicators by region both support the likelihood of lower seroprevalence rates in the western parts of the country and higher rates in the eastern region. Similar within-country differences in hepatitis A profiles have been observed in other countries. For example, rates are higher in northern than southern Brazil 66 , they are higher in southern than northern Mexico 67 and they are higher in southern than northern Italy 68 . There are also notable differences in the hepatitis A endemicity profiles between urban and rural areas of Turkey. However, even some higherincome areas had hepatitis A profiles suggesting high rather than intermediate endemicity.
Internal and external migration may explain some of those observations especially for cities such as Izmir and Canakkale. Additional studies from across Turkey-ones that use population-based samples with sufficiently large numbers of participants from a range of age groups, including children-are needed to confirm the current heterogeneity of hepatitis A seroprevalence and the drivers of those profiles.
HAV endemicity is an indicator of both current and past hepatitis A incidence rates. An age at midpoint of population immunity in children who are not yet of school age-a "very high" endemicity-means that the majority of very young children in a population have been exposed to the virus early in their lives. Places categorized as having very high endemicity in this study can be assumed to have a high current HAV incidence rate. By contrast, an age at midpoint of population immunity in The uptick in cases from 2010 to 2011 was attributed to an outbreak among asylum-seekers from Syria who had settled in the border city of Hatay 69 . New population-based seroprevalence studies in Turkey will need to differentiate between long-term residents and those who have migrated from other parts of Turkey or who have immigrated to Turkey from nearby countries such as Syria that have higher rates of hepatitis A due to current and/or historic conflicts that have disrupted public health 11 .
Future seroprevalence studies involving participants born after the introduction of hepatitis A vaccine as part of the routine childhood immunization schedule in Turkey in 2012 will also have to account for the possibility that the seropositivity rate in those age cohorts reflects vaccination status rather than natural infection. Universal childhood vaccination is recommended for places with intermediate endemicity, while targeted vaccination is considered most appropriate in places with low endemicity 4, 70 . Based on those guidelines, Turkey 's current policy of recommending hepatitis A immunization for all children without contraindications 3, 4 is an appropriate one and is likely to remain the best option for at least the next decade or two. The incidence rate will likely further decrease as a function of both the vaccination program and ongoing infrastructural development. At the same time, it is likely that there will be new outbreaks associated with human migration and international trade. Some outbreaks may occur in refugee camps, as was observed in 2011 69 ; others may be associated with travel or foods that spark sustained local outbreaks among susceptible adults and unvaccinated children. A strengthened health surveillance system and nationwide serosurveys will be valuable for monitoring emerging threats to public health along with tracking rates of uptake of childhood vaccination. 
